CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Xu, Lin ^a   Wang, Chunhong ^b   Wen, Zhenke ^c   Zhou, Ya ^a   Liu, Zhongmin ^d   Liang, Yongjie ^d   Xu, Zengguang ^d   Ren, Tao ^d  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b Qingdao Chest Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 4; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; AGED; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL POLARITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; THERAPY EFFECT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; TUMOR CELL CULTURE;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TH17 CELLS; TUMOR CELLS, CULTURED;

EID: 78349250943     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/410893     Document Type: Article

References (31)

1. Fujiwara H., Ochi T., Yasukawa M., Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia Journal of Biomedicine and Biotechnology 2010 2010 10
2. Coccoris M., Straetemans T., Govers C., Lamers C., Sleijfer S., Debets R., T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies Expert Opinion on Biological Therapy 2010 10 4 547 562
3. Bachmann M., Cartellieri M., Feldmann A., Bippes C., Stamova S., Wehner R., Temme A., Schmitz M., Chimeric antigen receptor-engineered T cells for immunotherapy of cancer Journal of Biomedicine and Biotechnology 2010 2010 13
4. Rosenberg S. A., Restifo N. P., Yang J. C., Morgan R. A., Dudley M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nature Reviews Cancer 2008 8 4 299 308
5. Dudley M. E., Rosenberg S. A., Adoptive-cell-transfer therapy for the treatment of patients with cancer Nature Reviews Cancer 2003 3 9 666 675
6. Rosenberg S. A., Sherry R. M., Morton K. E., Scharfman W. J., Yang J. C., Topalian S. L., Royal R. E., Kammula U., Restifo N. P., Hughes M. S., Schwartzentruber D., Berman D. M., Schwarz S. L., Ngo L. T., Mavroukakis S. A., White D. E., Steinberg S. M., Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma The Journal of Immunology 2005 175 9 6169 6176
7. Xue S.-A., Gao L., Thomas S., Hart D. P., Xue J. Z., Gillmore R., Voss R.-H., Morris E., Stauss H. J., Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice Haematologica 2010 95 1 126 134
8. Mangsbo S. M., Sandin L. C., Anger K., Korman A. J., Loskog A., Ttterman T. H., Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy Journal of Immunotherapy 2010 33 3 225 235
9. Karbach J., Gnjatic S., Bender A., Neumann A., Weidmann E., Yuan J., Ferrara C. A., Hoffmann E., Old L. J., Altorki N. K., Jger E., Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival International Journal of Cancer 2010 126 4 909 918
10. Ren T., Wen Z.-K., Liu Z.-M., Qian C., Liang Y.-J., Jin M.-L., Cai Y.-Y., Xu L., Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients Cancer Investigation 2008 26 5 448 455
11. Xu L., Xu W., Qiu S., Xiong S., Enrichment of CCR 6+ Foxp 3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer Clinical Immunology 2010 135 3 466 475
12. Xu L., Xu W., Jiang Z., Zhang F., Chu Y., Xiong S., Depletion of CD8+ CD25high regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy Cancer Biology and Therapy 2009 8 1 66 72
13. Maruyama T., Kono K., Mizukami Y., Kawaguchi Y., Mimura K., Watanabe M., Izawa S., Fujii H., Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer Cancer Science 2010 101 9 1947 1954
14. Martin-Orozco N., Dong C., The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Current Opinion in Investigational Drugs 2009 10 6 543 549
15. Martin-Orozco N., Muranski P., Chung Y., Yang X. O., Yamazaki T., Lu S., Hwu P., Restifo N. P., Overwijk W. W., Dong C., T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity Immunity 2009 31 5 787 798
16. Molavi O., Ma Z., Hamdy S., Lai R., Lavasanifar A., Samuel J., Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model Immunology and Cell Biology 2008 86 6 506 514
17. Weiner G. J., CpG oligodeoxynucleotide-based therapy of lymphoid malignancies Advanced Drug Delivery Reviews 2009 61 3 263 267
18. Wu A., Oh S., Gharagozlou S., Vedi R. N., Ericson K., Low W. C., Chen W., Ohlfest J. R., In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma Journal of Immunotherapy 2007 30 8 789 797
19. Hiraoka K., Yamamoto S., Otsuru S., Nakai S., Tamai K., Morishita R., Ogihara T., Kaneda Y., Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides The Journal of Immunology 2004 173 7 4297 4307
20. Song S., Wang Y., Zhang Y., Wang F., He Y., Ren D., Guo Y., Sun S., Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG Cancer Letters 2007 256 1 90 100
21. Wang L., Yi T., Kortylewski M., Pardoll D. M., Zeng D., Yu H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway Journal of Experimental Medicine 2009 206 7 1457 1464
22. Kawakami Y., Tomimori Y., Yumoto K., Hasegawa S., Ando T., Tagaya Y., Crotty S., Kawakami T., Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum Journal of Experimental Medicine 2009 206 6 1219 1225
23. Langowski J. L., Zhang X., Wu L., Mattson J. D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R. A., Oft M., IL-23 promotes tumour incidence and growth Nature 2006 442 7101 461 465
24. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W., Endogenous IL-17 contributes to reduced tumor growth and metastasis Blood 2009 114 2 357 359
25. Hu J., Yuan X., Belladonna M. L., Ong J. M., Wachsmann-Hogiu S., Farkas D. L., Black K. L., Yu J. S., Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells Cancer Research 2006 66 17 8887 8896
26. Muranski P., Boni A., Antony P. A., Cassard L., Irvine K. R., Kaiser A., Paulos C. M., Palmer D. C., Touloukian C. E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C. S., Kerstann K. W., Feigenbaum L., Chan C.-C., Restifo N. P., Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 2008 112 2 362 373
27. Hus I., Maciag E., Roliski J., The role of Th17 cells in anti-cancer immunity Postpy Higieny i Medycyny Dowiadczalnej 2010 64 244 250
28. Ji Y., Zhang W., Th17 cells: positive or negative role in tumor? Cancer Immunology, Immunotherapy 2010 59 7 979 987
29. Su X., Ye J., Hsueh E. C., Zhang Y., Hoft D. F., Peng G., Tumor microenvironments direct the recruitment and expansion of human Th17 cells The Journal of Immunology 2010 184 3 1630 1641
30. Murugaiyan G., Saha B., Protumor vs antitumor functions of IL-17 The Journal of Immunology 2009 183 7 4169 4175
31. Zou W., Restifo N. P., TH17 cells in tumour immunity and immunotherapy Nature Reviews Immunology 2010 10 4 248 256